Evidence map›Paper›PMID 42177403›Full record

ArticleBMC immunology2026

Deficient TRPM3-linked mitochondrial Ca

Chandi Tabeth Magawa, Natalie Eaton-Fitch, Katsuhiko Muraki, Sonya Marshall-Gradisnik

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Chandi Tabeth MagawaNational Centre for Neuroimmunology and Emerging Diseases, Griffith University, Gold Coast, Australia. chandi.magawa@griffithuni.edu.au.ORCID http://orcid.org/0000-0002-4351-7179
Natalie Eaton-FitchNational Centre for Neuroimmunology and Emerging Diseases, Griffith University, Gold Coast, Australia.
Katsuhiko MurakiConsortium Health International for Myalgic Encephalomyelitis, Griffith University, Gold Coast, Australia.
Sonya Marshall-GradisnikNational Centre for Neuroimmunology and Emerging Diseases, Griffith University, Gold Coast, Australia.

Funding

Alison Hunter Memorial Foundation 4570Blake Beckett Trust Foundation 4579Henty Community 4879Henty Lions Club 4880McCusker Charitable Foundation 49979National Health and Medical Research Council 1199502Talei Stewart 0000The Stafford Fox Medical Research Foundation 489798
6 · The paper itself

Abstract

introductionMyalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) is a multisystemic illness, commonly associated with dysregulation of the immune system including reduced cytotoxicity of natural killer (NK) cells and post-exertional neuroimmune exhaustion. Previously, transient receptor potential melastatin 3 (TRPM3) ion channel impairment associated with reduced Ca

methodFluorescence live-cell imaging was used to investigate Ca

resultsCytosolic Ca

conclusionThe results demonstrate that altered TRPM3-mediated cytosolic Ca

Indexed as

CalciumFatigue Syndrome, ChronicKiller Cells, NaturalMitochondriaTRPM Cation ChannelsAdultCalcium SignalingCells, CulturedFemaleHumansMaleMiddle AgedPregnenoloneCalciumPregnenolonepregnenolone sulfateTRPM3 protein, humanTRPM Cation ChannelsCalcium signallingChronic fatigue syndromeME/CFSMitochondriaMyalgic encephalomyelitisNatural killer cellsTRP channelsTRPM3

Identifiers

PMID42177403
PMCPMC13386572

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.